[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-351019-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-351019-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","leveraging-landmark-analysis-for-tailored-surveillance-in-stage-i-non-small-cell-lung-cancer","Leveraging Landmark Analysis for Tailored Surveillance in Stage I Non-Small-Cell Lung Cancer","","Current NSCLC follow-up guidelines provide limited guidance on surveillance duration after curative resection. This study retrospectively analyzed 759 patients with pathological stage I NSCLC without prior lung cancer who underwent surgery from January 2003 to December 2018. Overall survival, relapse incidence, and new primary lung cancer incidence were evaluated, including landmark analysis beyond 5 years at 10 years among 5-year event-free survivors. Histology and lung nodules were key determinants of late events, supporting a risk-stratified, tailored surveillance strategy with de-escalation for low-risk patients.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/leveraging-landmark-analysis-for-tailored-surveillance-in-stage-i-non-small-cell-lung-cancer/351019/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/leveraging-landmark-analysis-for-tailored-surveillance-in-stage-i-non-small-cell-lung-cancer/351019.png","ImageObject",300,407,{"name":42,"@type":43},"Oliver","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",17,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What clinical gap does this study address in stage I non-small-cell lung cancer follow-up?","Question",{"text":63,"@type":64},"Existing NSCLC guidelines lack specific recommendations on how long surveillance should continue after curative resection, motivating an analysis of long-term outcomes and surveillance patterns.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was long-term surveillance impact evaluated?",{"text":68,"@type":64},"The study used retrospective survival and incidence analyses and applied landmark analysis of overall survival, relapse incidence, and new primary lung cancer incidence at 10 years, restricted to individuals event-free at 5 years.",{"name":70,"@type":61,"acceptedAnswer":71},"Which factors were most important for predicting late events?",{"text":72,"@type":64},"Histology and the presence of lung nodules were key determinants of late events, with carcinoid tumors and adenocarcinoma without lung nodules showing lower risks of relapse and new primary tumors.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},351019,1790161833,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":33,"preview_urls":147},8796095461610,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Article  \nLeveraging Landmark Analysis for Tailored Surveillance in Stage I Non-Small-Cell Lung Cancer †  \nGiovanni Leuzzi 1, *, Federica Sabia 1, Matteo Calderoni 1, Clarissa Uslenghi 1, Ugo Pastorino 2,  \nAlfonso Marchianò 3, Michele Ferrari 1, Alessandro Pardolesi 1, Daniele Lorenzini 4,5, Giuseppe Lo Russo 6, Claudia Proto 6, Arsela Prelaj 6 and Piergiorgio Solli 1  \nAcademic Editor: Tsutani Yasuhiro  \nReceived: 13 January 2026  \nAccepted: 15 January 2026  \nPublished: 24 January 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \n1 Division of Thoracic Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy;  \nfederica.sabia@istitutotumori.mi.it (F.S.); matteo.calderoni@istitutotumori.mi.it (M.C.);  \nclarissa.uslenghi@istitutotumori.mi.it (C.U.); [michele.ferrari@istitutotumori.mi.it](michele.ferrari@istitutotumori.mi.it) (M.F.);  \nalessandro.pardolesi@istitutotumori.mi.it (A.P.); piergiorgio.solli@istitutotumori.mi.it (P.S.)  \n2 Lung Cancer Prevention Research, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy; [ugo.pastorino@me.com](ugo.pastorino@me.com)  \n3 Department of Radiology, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy;  \nalfonso.marchiano@istitutotumori.mi.it  \n4 Department of Diagnostic Innovation, Fondazione IRCCS Istituto Nazionale Dei Tumori, 20133 Milan, Italy; daniele.lorenzini@istitutotumori.mi.it  \n5 Department of Oncology and Hemato-Oncology, University of Milan, 20122 Milan, Italy  \n6 Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy;  \ngiuseppe.lorusso@istitutotumori.mi.it (G.L.R.); claudia.proto@istitutotumori.mi.it (C.P.);  \narsela.prelaj@istitutotumori.mi.it (A.P.)  \n* Correspondence: giovanni.leuzzi@istitutotumori.mi.it; Tel.: +39-0223902600  \n† Accepted as poster presentation at Leuzzi, G.; Sabia, F.; Calderoni, M.; Uslenghi, C.; Pastorino, U.; AlfonsoMarchianò; Ferrari, M.; Pardolesi, A.; Stanzi, A.; Russo, G.L.; et al. Tailored Follow-Up: Leveraging Landmark Analysis for Subgroup-Specific Surveillance in Stage I Non-Small-Cell Lung Cancer. In Proceedings of the 62nd STS Annual Meeting, New Orleans, LA, USA, 29 January–1 February 2026 .  \nSimple Summary  \nThis study investigated the long-term outcomes and surveillance patterns in 759 patients who underwent surgery for pathological stage I Non-Small-Cell Lung Cancer (NSCLC) . We sought to provide evidence to refine current follow-up guidelines, which often lack specific recommendations regarding the optimal duration of surveillance after curative resection. Crucially, the study found that histology and the presence of lung nodules (LNs) were key determinants of late events. Patients with carcinoid tumors and those with adenocarcinoma without LNs demonstrated a significantly lower risk of relapse and new primary tumors compared to high-risk groups. Focusing specifically on 5-year event-free survivors (5y-EFSs), these patients exhibited excellent conditional 10-year OS (92%), but the risk of late events persisted for those with stage IB disease or pre-existing/new LNs. Based on these findings, we propose a tailored, risk-stratified surveillance strategy. This model supports de-escalating follow-up intensity for patients identified as low-risk (such as those with carcinoid and adenocarcinoma without LNs) while ensuring that high-risk individuals receive continued, intensive monitoring to promptly detect potentially curable late events.  \nAbstract  \nBackground: Current guidelines for NSCLC follow-up lack specific recommendations on surveillance duration. This study aims to analyze survival and surveillance data in resected stage I NSCLC. Methods: We retrospectively reviewed 759 pathological stage INSCLC (9thTNM ed.) patients with no history of lung cancer (LC) undergoing surgery from Ja","cbCaia1cVfAjh8e2","https://ap.wps.com/l/cbCaia1cVfAjh8e2","pdf",1472541,14,"English","# Simple Summary\n# Abstract\n# 1. Introduction\n## Clinical problem and rationale\n## Follow-up goals (recurrence and new primary cancer)","[{\"question\":\"What clinical gap does this study address in stage I non-small-cell lung cancer follow-up?\",\"answer\":\"Existing NSCLC guidelines lack specific recommendations on how long surveillance should continue after curative resection, motivating an analysis of long-term outcomes and surveillance patterns.\"},{\"question\":\"How was long-term surveillance impact evaluated?\",\"answer\":\"The study used retrospective survival and incidence analyses and applied landmark analysis of overall survival, relapse incidence, and new primary lung cancer incidence at 10 years, restricted to individuals event-free at 5 years.\"},{\"question\":\"Which factors were most important for predicting late events?\",\"answer\":\"Histology and the presence of lung nodules were key determinants of late events, with carcinoid tumors and adenocarcinoma without lung nodules showing lower risks of relapse and new primary tumors.\"}]","Leveraging Landmark Analysis for Tailored Surveillance in Stage I Non-Small-Cell Lung Cancer | PDF",1790092294,35,[148,152,156,160],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a943d08de07004ba5fc750bc04a4ffeb.webp",983,1390,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7d38c896b19acd0937e64936903b2cd0.webp",982,1388,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e36ef65bac168678fd6b89118a5be951.webp",981,1387,{"page_no":33,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ee0dcd2240d6a6e4631eddf2cec842e9.webp",980,1385]